Related Experiment Videos
Abstract:
Platelet functions were studied in 16 patients with multiple myeloma (MM) and 4 with primary macroglobulinemia (PM). The fall in immunoglobulins on therapy was correlated with the status of platelet function. Effect of incubation of normal platelets with immunoglobulins derived from these patients on kaolin-induced platelet factor 3 (PF3) release was studied to elucidate the mechanism of platelet function defect. Results show increased bleeding time, absence or poor platelet adhesion and aggregation, poor PF3 availability and reduced total PF3 in platelets more consistently in PM but to a lesser extent in MM. Normalisation or partial reduction in globulins on therapy was associated with improvement in platelet functions. Incubation of normal platelets with immunoglobulins enhanced the kaolin-induced PF3 availability. It is suggested that in vivo platelet activation may bring about the PF3 release which subsequently manifests as poor PF3 availability and reduction in its total contents.
Insights
Patients with multiple myeloma and primary macroglobulinemia exhibit impaired platelet function, including poor adhesion and aggregation. Immunoglobulins from these patients may cause platelet defects by affecting platelet factor 3 (PF3) release.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Platelet dysfunction is observed in patients with hematologic malignancies.
- The specific mechanisms underlying platelet defects in multiple myeloma (MM) and primary macroglobulinemia (PM) require further elucidation.
Purpose of the Study:
- To investigate platelet functions in patients with MM and PM.
- To correlate changes in immunoglobulin levels with platelet function during therapy.
- To explore the role of patient-derived immunoglobulins in platelet dysfunction.
Main Methods:
- Studied platelet function (adhesion, aggregation, platelet factor 3 (PF3) release) in 16 MM and 4 PM patients.
- Correlated immunoglobulin levels with platelet function status during treatment.
- Incubated normal platelets with patient-derived immunoglobulins to assess effects on kaolin-induced PF3 release.
Main Results:
- Patients, particularly those with PM, showed increased bleeding time, poor platelet adhesion and aggregation, and reduced PF3 availability and content.
- Improvement in platelet function was observed with normalization or reduction of globulin levels during therapy.
- Incubation of normal platelets with patient immunoglobulins enhanced kaolin-induced PF3 release.
Conclusions:
- Platelet dysfunction in MM and PM is associated with altered immunoglobulin levels.
- Patient immunoglobulins may contribute to platelet defects by affecting PF3 release.
- In vivo platelet activation might lead to PF3 release, resulting in impaired platelet function.